Evidence Level:Sensitive: B - Late Trials
Title:
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Excerpt:KEYNOTE-063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second-line therapy in Asian patients with advanced programmed death ligand 1 (PD-L1)-positive (combined positive score ≥1) gastric/gastroesophageal junction (GEJ) cancer….Median OS was 8 months (95% confidence interval [CI], 4-10 months) with pembrolizumab versus 8 months (95% CI, 5-11 months) with paclitaxel (hazard ratio [HR], 0.99; 95% CI, 0.63-1.54).
Evidence Level:Sensitive: B - Late Trials
Title:
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Excerpt:Pembrolizumab demonstrated a trend toward improved OS vs paclitaxel in the CPS ≥ 1 population (HR, 0.81); 24-month OS rates: 19.9% vs 8.5%....In this long-term analysis, 2L pembrolizumab did not significantly improve OS but was associated with higher 24-month OS rates than paclitaxel. Pembrolizumab also increased OS benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer TRAEs than paclitaxel.
DOI:10.1007/s10120-021-01227-z.
Evidence Level:Sensitive: B - Late Trials
Title:
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Excerpt:NON-SUPPORTIVE EVIDENCE:...pembrolizumab was noninferior to chemotherapy for OS in patients with CPS of 1 or greater (median, 10.6 vs 11.1 months; hazard ratio [HR], 0.91; 99.2% CI, 0.69-1.18). Pembrolizumab monotherapy was not superior to chemotherapy in patients with CPS of 1 or greater.
Secondary therapy:cisplatin + 5-fluorouracil; capecitabine
DOI:doi:10.1001/jamaoncol.2020.3370
Evidence Level:Sensitive: B - Late Trials
Title:
O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Excerpt:Among patients with PD-L1–positive advanced gastric/GEJ cancer, OS on subsequent therapy was better in the pembrolizumab group than the paclitaxel group, with a possibly greater effect when an anti-VEGF plus taxane was given as subsequent therapy.
DOI:https://doi.org/10.1016/j.annonc.2020.04.065
Evidence Level:Sensitive: B - Late Trials
Title:
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Excerpt:Pembrolizumab prolonged OS vs paclitaxel in PD-L1–positive patients (Table). No significant differences appeared between groups in PFS (Table). Objective response rate (ORR) was higher for pembrolizumab in the CPS ≥10 group, and DOR was longer with pembrolizumab using all CPS cutoffs (Table).
DOI:10.1200/JCO.2020.38.15_suppl.4503
Evidence Level:Sensitive: B - Late Trials
New
Title:
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Excerpt:...patients with a programmed cell death ligand 1 (PD-L1)...Median overall survival was 9·1 months (95% CI 6·2-10·7) with pembrolizumab and 8·3 months (7·6-9·0) with paclitaxel (hazard ratio [HR] 0·82, 95% CI 0·66-1·03; one-sided p=0·0421)...Median progression-free survival was 1·5 months (95% CI 1·4-2·0) with pembrolizumab and 4·1 months (3·1-4·2) with paclitaxel (HR 1·27, 95% CI 1·03-1·57)...Pembrolizumab had a better safety profile than paclitaxel.
DOI:10.1016/S0140-6736(18)31257-1
Evidence Level:Sensitive: B - Late Trials
New
Title:
KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction
Excerpt:Eligible patients were randomized in a 1:1 ratio to pembrolizumab 200 mg Q3W or paclitaxel 80 mg/m2....In post-hoc analysis, the pembrolizumab treatment effect for OS was also greater in patients with CPS ≥10 (median OS 10.4 mo vs 8.0 mo; HR 0.64, 95% CI 0.41-1.02) and in patients with MSI-H tumors.
DOI:https://doi.org/10.1093/annonc/mdy208.004
Evidence Level:Sensitive: C1 - Off-label
(Approved for Non Small Cell Lung Cancer)
New
Excerpt:Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Excerpt:Willing to provide tissue for PD-L1 biomarker analysis from newly-obtained and/or archival tissue...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Excerpt:...Human epidermal growth factor receptor 2- (HER2/neu-) negative and programmed cell death ligand 1 (PD-L1)-positive...
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial
Excerpt:Of the 33 patients, 12 were MSI-H, 3 EBV (+), and 27 had PDL1 expression with CPS >/= 1%. Tumors were of advanced clinical stage with 84.8% ≥ cT3 and 57.6% cN(+). All patients received two cycles of neoadjuvant pembrolizumab...treatment effect was seen in 46%, down-staging in 50%, and complete pathologic response seen in 3 patients, 2 of whom has MSI-H tumors and one whose tumor was PDL1+...This study presents a novel and effective paradigm for the management of localized gastric cancer...
DOI:10.1200/JCO.2023.41.16_suppl.e16073
Evidence Level:Sensitive: C3 – Early Trials
Title:
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Excerpt:Eligible patients were randomly assigned 1:1:1 to pembrolizumab 200 mg, pembrolizumab plus chemotherapy (cisplatin + 5-fluorouracil or capecitabine)...In the programmed death ligand 1 combined positive score ≥10 population, median overall survival was also numerically longer with pembrolizumab versus chemotherapy (28.5 vs 14.8 months; hazard ratio, 0.43; 95% confidence interval, 0.21-0.89)...pembrolizumab monotherapy was associated with numerically improved overall survival and a favourable tolerability profile versus chemotherapy in Asians with programmed death ligand 1-positive advanced gastric cancer/gastrooesophageal junction cancer.
Secondary therapy:capecitabine; cisplatin + 5-fluorouracil
Evidence Level:Sensitive: C3 – Early Trials
Title:
"Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score =10"
Excerpt:"...pembrolizumab monotherapy given as first-line (KEYNOTE-062), second-line (KEYNOTE061), and third-line and later (KEYNOTE-059) therapy showed a
clinically meaningful median and long-term survival benefit in
patients with CPS ≥ 10 gastric or GEJ tumors and more durable
responses compared with chemotherapy."
Evidence Level:Sensitive: C3 – Early Trials
Title:
S-1+oxaliplatin with pembrolizumab for advanced gastric cancer: The cohort 1 in a phase IIb KEYNOTE-659 study.
Excerpt:This study showed the encouraging efficacy and manageable safety of SOX with P therapy as a first line in pts with HER2-negative, PD-L1-positive AGC.
Secondary therapy:oxaliplatin + gimeracil/oteracil/tegafur
Evidence Level:Sensitive: C3 – Early Trials
Title:
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS =10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.
Excerpt:In study 059, 46 pts in cohort 1 with PD-L1 CPS ≥10 received pembro. In study 061, 108 pts with PD-L1 CPS ≥10 received pembro (n=53) or chemotherapy (chemo; n=55)...Collectively, these data indicate that 1L, 2L, and 3L+ pembro monotherapy showed clinically meaningful efficacy in CPS ≥10, with a more durable response than chemotherapy.
Evidence Level:Sensitive: C3 – Early Trials
Title:
Mini Oral session - Gastrointestinal tumours
Excerpt:Pembro prolonged OS vs chemo in CPS ≥10 (median 17.4 vs 10.8 mo; HR 0.69; 95% CI 0.49-0.97)…
Evidence Level:Sensitive: C3 – Early Trials
New
Title:
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Excerpt:Objective response rate and median (range) response duration were 15.5% (95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4% (95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1-positive and PD-L1-negative tumors, respectively.
DOI:10.1001/jamaoncol.2018.0013